Document is current

Article History

Received: 5 June 2024

Revised: 5 June 2024

Accepted: 13 July 2024

First Online: 1 August 2024

Compliance with ethical standards

:

: The scientific guarantor of this publication is Sabine Dettmer.

: The authors of this manuscript declare relationships with the following companies: S.D. reports grants from Siemens; personal honoraria for lectures from !DE Werbeagentur GmbH, Boehringer Ingelheim, med update GmbH. M.H.N. reports fees for clinical trial participation from Astra-Zeneca, Insmed, LMU Tropeninstitut, Lophius, and R-Biopharm to her institution; personal honoraria for lectures from Insmed. F.C.R. reports grants from the German Center for Lung Research (DZL), the German Center for Infection Research (DZIF), the Innovative Medicines Initiative (IMI; EU/EFPIA), and the iABC Consortium (including Alaxia, Basilea, Novartis, and Polyphor), Mukoviszidose Institute, Novartis, and Insmed Germany paid to his institution; fees for clinical trial participation from AstraZeneca, Boehringer Ingelheim, Insmed, Novartis, University of Dundee, Vertex, and Zambon paid to his institution; personal consulting fees from Parion Sciences, Grifols, Zambon, Insmed, and Helmholtz Center for Infection Research; personal honoraria for lectures from!DE Werbeagentur GmbH, Interkongress GmbH, AstraZeneca, Insmed, Grifols, University Hospital Frankfurt; as well as honorary (unpaid) commitment as coordinator of the ERN-LUNG Bronchiectasis Core Network, co-chair of the German Bronchiectasis Registry PROGNOSIS, member of the steering committee of the European Bronchiectasis Registry EMBARC, and principal investigator of the German Center for Lung Research (DZL). J.R. reports grants from the German Center for Lung Research (DZL), the German Center for Infection Research (DZIF), the Bundesministerium für Bildung und Forschung (BMBF), and the Bundesministerium für Gesundheit (BMG) paid to her institution; personal honoraria for lectures from AstraZeneca, Berlin-Chemie, Insmed, GSK, MedUpdate, MSD, Shionogi, ThermoFisher personal payments for participation on an advisory board from Insmed, GSK, GILEAD, ThermoFisher and Shionogi. S.W., H.M., O.J., N.T., R.E., and F.W. declare that they have no competing interests.

: Only simple statistical tests were used. One of the authors has sufficient statistical expertise.

: Only if the study is on human subjects: written informed consent was not required for this study because it is a retrospective study and consent was waived by the Institutional Review Board. In the treatment contract, the patients agree that data may be used for clinical studies. Only if the study is on animals: this study is not on animals.

: This study has been approved by the Internal Review Board (no. 8953_BO_K_2020) at the Hannover Medical School in Hannover, Germany, and also by the Internal Review Board (no. S-619/2023) at the Medical Faculty of Heidelberg University, Heidelberg Germany. The Review Board of Bayerische Landesärztekammer took the position that no separate application was necessary for Gauting, Germany (mb23061).

: There are no study subjects or cohorts overlap.

: